PLUS THERAPEUTICS INC PSTV 深 滬
已收盤 11-21 16:00:00 美东时间
0.5327
+0.044
+9.07%
華盛通- 最 高0.534
- 今 開0.4921
- 成交量 443.37万股
- 最 低 0.4803
- 昨 收 0.4884
- 總市值 7297.99万
- 52周最高 2.3099
- 市盈率 靜 --
- 換手率 3.24%
- 52周最低 0.1634
- 委 比 -14.12%
- 總股本 1.37亿
- 歷史最高 343.35
- 量 比 0.53
- 振 幅 11.00%
- 歷史最低 0.1634
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Plus Therapeutics' CNSide Diagnostics Signs National Agreement With Humana To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Laboratory Developed Test
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a national agreement with Humana, Inc. (NYSE:HUM),
11-20 20:34
Plus Therapeutics granted 180-day to regain compliance with Nasdaq
Plus Therapeutics (PSTV) announced on Monday that it has received an additional 180-day extension period from the Nasdaq to regain compliance with the $1.00 minimum bid price requirement as per Nasdaq...
11-17 21:06
Plus Therapeutics Gains Nasdaq Extension for Compliance
Plus Therapeutics ( ($PSTV) ) has provided an announcement. On November 17, 202...
11-17 20:58
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
HC Wainwright & Co. Maintains Buy on Plus Therapeutics, Lowers Price Target to $2
HC Wainwright & Co. analyst Sean Lee maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from $3 to $2.
11-03 19:31
Plus Therapeutics Q3 EPS $(0.04) Misses $(0.02) Estimate, Sales $1.397M Miss $1.500M Estimate
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.02) by 100 percent. This is a 89.19 percent increase over losses of $(0.37) per share from
10-31 04:28
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.
10-21 20:28
Plus Therapeutics Signs Lease Agreement in Houston
An update from Plus Therapeutics ( ($PSTV) ) is now available. On October 16, 2...
10-21 19:50
Plus Therapeutics Expands CNSide Diagnostic Business, Lands National Coverage Deal With UnitedHealthcare
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers,
10-21 19:42
